







716Macular arteritis in an HIV-infected patient
improving with adherence toantiretroviral therapy
Elisabeth Bodde, MD,a Jeffrey Damman, MD, PhD,b and Martijn B. A. van Doorn, MD, PhDa
Rotterdam, the NetherlandsINTRODUCTION
Macular arteritis is a cutaneous vasculitis charac-
terized by asymptomatic erythematous or hyperpig-
mented macules on clinical examination and by
the histopathologic hallmarks of a lymphocyte-
predominant small- to medium-sized vessel arteritis.
Macular arteritis mostly affects middle-aged
women, usually from North African or Asian coun-
tries.1,2 The lower extremities are predominantly
involved, and besides minimal pruritus, in most
cases the skin lesions are asymptomatic.3CASE REPORT
A 33-year-old HIV-positive female patient pre-
sented at our outpatient clinic, with a 6-month
history of progressive brown macules on her arms,
legs, and abdomen. Besides incidental complaints of
slight itching, the skin lesions were asymptomatic.
She had previously been treated with topical ste-
roids, without any effect. Subsequently, she was
treated with combination antiretroviral therapy,
consisting of dolutegravir and emtricitabine/tenofo-
vir disoproxil.
On physical examination, we observed numerous
ill-defined hyperpigmented macules on her arms,
legs, and abdomen, some of which were slightly
erythematous (Fig 1). The skin lesions were pre-
dominantly macular, but some exhibited slight
induration.
Histopathologic examination revealed a small- to
medium-sized artery with transmural influx of
lymphocytes and prominent concentric intimal
fibrinoid necrosis (Fig 2). An elastin stain showed
an intact internal elastic lamina as proof of an
affected artery (Fig 3). In addition, perivascular
adventitial inflammation was noted, with presence
of lymphocytes, eosinophils, and few plasma cells.Departments of Dermatology and Venereologya and
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diagnosis of macular arteritis.
The patient admitted having poor adherence to
the antiretroviral therapy, which was confirmed by a
reduced CD4 T lymphocyte count. By intensifying
surveillance through home care, her treatment
adherence improved, which eventually led to the
normalization of her CD4 T lymphocyte count.
Subsequently, the skin lesions faded and eventually
disappeared.DISCUSSION
A total of 50 cases of macular arteritis have
been described in the literature.4 To our knowledge,
only 1 case similar to ours has been reported previ-
ously, describing macular arteritis in an African
woman with HIV and hepatitis B coinfection.5 HIV
patients with small- to medium-vessel vasculitis that
improved after antiretroviral therapy have been
described previously in the literature. These studies
included patients with intracerebral and intra-
abdominal vasculitis,6-8 as well as skin lesions.9-13
Although vasculitis in these patients also resolved
after antiviral therapy, in contrast to our case, none of
these patients presented with macular skin lesions.
The estimated incidence of vasculitis in HIV-
positive patients is 1% and includes all types of
vasculitis (small-, medium-, and large-vessel vascu-
litis). Different mechanisms of different types of
vasculitis in HIV patients have been identified, such
as the direct invasion of vascular tissue by HIV
particles. An indirect effect of HIV infection is the
elevation of CD8 T cells in active HIV infections,
which causes increased release of growth factors,
cytokines, adhesion molecules, superantigens, and
immunocomplexes.14 In macular arteritis, vasculitis
is characterized by an endarteritic endotheliopathyJAAD Case Reports 2020;6:716-8.
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Fig 1. Clinical photograph of the patient.
Fig 2. Subcutaneous small- to medium-sized arteritis
showing a concentric ring of fibrin deposition primary
localized to the intima but with extension into the medial
wall. There is endothelial cell swelling and lymphocytic
endothelialitis. Also note the extensive (peri)adventitial
infiltrate composed of lymphocytes, histiocytes, plasma
cells, and eosinophils but without neutrophils.
Fig 3. An elastin stain revealed an almost intact internal
elastic lamina.
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lacking transmural fibrinoid necrosis, with preserva-
tion of the vascular lamina. Macular arteritis is
clinically expressed by limited cutaneous manifesta-
tions with chronic indolent course and absence of
progression to systemic disease.
There has been debate in the literature about
whether macular arteritis represents an indolent
nonnodular variant of cutaneous polyarteritis no-
dosa or a distinct entity.4,15-21
Cutaneous polyarteritis nodosa can classically
present with tender dermal nodules, palpable pur-
pura, and ulcers, while macular arteritis shows
features of pigmented macules, livedo racemosa, or
both, as illustrated in the current case. Although
cutaneous polyarteritis nodosa and macular arteritis
show distinct clinical presentations, it is hypothe-
sized that macular arteritis could represent an early
stage in the spectrum of cutaneous polyarteritis
nodosa. An additional entity that fueled this discus-
sion is the introduction of the term ‘‘lymphocytic
thrombophilic arteritis.’’ Patients described with
lymphocytic thrombophilic arteritis show clinical
features in between those of macular arteritis and
cutaneous polyarteritis nodosa, with pigmentedmacules on the one hand and nodules on the other.21
The authors who introduced the term suggested
replacing macular arteritis with lymphocytic throm-
bophilic arteritis, because in their opinion the latter
describes the pathophysiology of the disease more
accurately. Others, however, have suggested
reserving lymphocytic thrombophilic arteritis for
presentation with papules and macular arteritis
purely for the macular variant. They hypothesized
a spectrum of disease within macular arteritis, lym-
phocytic thrombophilic arteritis, and cutaneous pol-
yarteritis nodosa.16 In contrast, a recent systematic
review concluded that macular arteritis is distinct
from cutaneous polyarteritis nodosa primarily ac-
cording to the indolent stable course and lack of
systemic progression of macular arteritis versus
cutaneous polyarteritis nodosa. Although the dis-
eases are still under debate, the same systematic
review and most other studies now agree that mac-
ular arteritis and lymphocytic thrombophilic arteritis
are identical entities.19
On histopathology, cutaneous polyarteritis no-
dosa predominantly exhibits a transmural neutro-
philic vasculitis with destruction of the internal
elastic lamina, although subacute or reparative
phases can manifest as a lymphocytic vasculitis.
Because cases described as lymphocytic thrombo-
philic arteritis/macular arteritis always present with a
lymphocytic vasculitis, clinicopathologic correlation
is essential.
In line with our case, skin biopsies of lymphocytic
thrombophilic arteritis/macular arteritis have shown
dominant intimal concentric fibrin deposition and a
preserved internal elastic lamina. Therefore, it has
been suggested that lymphocytic thrombophilic
arteritis/macular arteritis, in contrast to cutaneous
polyarteritis nodosa, should be classified as a
lymphohistiocytic thrombophilic endovasculitis
(Fig 3).22 Although others have argued that a pre-
served internal elastic lamina can also be observed in
early stages of cutaneous polyarteritis nodosa, the
extensive, transmural, and above all lymphohistio-
cytic (and not neutrophilic) inflammation, as
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hypothesis of a thrombophilic endovasculitis in
lymphocytic thrombophilic arteritis/macular arteritis
could also play a role in our case because hyperco-
agulability can occur in an active HIV infection;
however, in our case coagulability tests were not
performed.23
Discriminating between both entities is of value
because response to treatment is substantially
different. Flares of cutaneous polyarteritis nodosa
are treated with high-dosage systemic glucocorti-
coids. Once disease control is established, a
glucocorticoid-sparing agent can be initiated, such
as dapsone, colchicine, or hydroxychloroquine.
This, in contrast to lymphocytic thrombophilic arter-
itis/macular arteritis, which has a much more indo-
lent character and has been shown to be very
treatment resistant. To our knowledge, there have
been no reported cases of patients with lymphocytic
thrombophilic arteritis/macular arteritis with pro-
gression to systemic vasculitis.19,20
The diagnosis of macular arteritis can be made for
a patient with macular skin lesions and the histologic
hallmarks of lymphohistiocytic thrombophilic endo-
vasculitis. In this patient, macular arteritis/lympho-
cytic thrombophilic arteritis significantly improved
with adherence to antiretroviral therapy.
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